XARELTO achieves net clinical benefit in treatment of patients with DVT

Links shared publicly online about this topic.

903
total visits

XARELTO achieves net clinical benefit in treatment of patients with DVT

Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.

View full resource at news-medical.net

Tags: Circulatory Disorders, Deep Venous Thrombosis, Stroke, Thrombotic Event, Anti-Clotting Medication, Xarelto, News